1. Home
  2. BEAM vs PFS Comparison

BEAM vs PFS Comparison

Compare BEAM & PFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Beam Therapeutics Inc.

BEAM

Beam Therapeutics Inc.

HOLD

Current Price

$27.29

Market Cap

2.3B

Sector

Health Care

ML Signal

HOLD

Logo Provident Financial Services Inc

PFS

Provident Financial Services Inc

HOLD

Current Price

$21.02

Market Cap

2.4B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
BEAM
PFS
Founded
2017
1839
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Savings Institutions
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
2.3B
2.4B
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
BEAM
PFS
Price
$27.29
$21.02
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
12
5
Target Price
$48.09
$23.00
AVG Volume (30 Days)
2.0M
933.6K
Earning Date
11-04-2025
01-27-2026
Dividend Yield
N/A
4.57%
EPS Growth
N/A
100.33
EPS
N/A
1.96
Revenue
$55,701,000.00
$836,917,000.00
Revenue This Year
N/A
$26.48
Revenue Next Year
$26.52
$14.19
P/E Ratio
N/A
$10.72
Revenue Growth
N/A
59.19
52 Week Low
$13.53
$14.34
52 Week High
$35.25
$21.09

Technical Indicators

Market Signals
Indicator
BEAM
PFS
Relative Strength Index (RSI) 59.24 74.79
Support Level $26.83 $19.09
Resistance Level $28.28 $21.09
Average True Range (ATR) 1.60 0.40
MACD 0.30 0.18
Stochastic Oscillator 69.34 88.55

Price Performance

Historical Comparison
BEAM
PFS

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.

About PFS Provident Financial Services Inc

Provident Financial Services Inc is the holding company for The Provident Bank, a community-oriented bank. The Company's operations are solely in the financial services industry and include providing traditional banking and other financial services to its customers. The Company operates in the geographical regions of northern and central New Jersey, Queens and Nassau Counties in New York and eastern Pennsylvania. The Company has a single reporting segment for financial reporting purposes. The majority of the revenue-generating activities that are components of non-interest income are These revenue streams can generally be classified into three broad categories: wealth management revenue, insurance agency income, and banking service charges and other fees.

Share on Social Networks: